EIN 31-1667995

Conquer Cancer and Conquer Cancer FDTN

IRS 501(c) type
501(c)(3)
Num. employees
0
Year formed
1999
Most recent tax filings
2022-12-01
Description
The Conquer Cancer Foundation funds breakthrough research and shares cutting edge cancer information with patients, caregivers and physicians. It is the philanthropic arm of The American Society of Clinical Oncology (ASCO).
Related structure
Conquer Cancer and Conquer Cancer FDTN is a subordinate organization under American Society of Clinical Oncology (ASCO).
Also known as...
Conquer Cancer Foundation of the American Society of Clinical Oncology; Conquer Cancer Foundation
Total revenues
$33,133,692
2022
Total expenses
$32,888,928
2022
Total assets
$98,117,170
2022
Num. employees
0
2022

Program areas at Conquer Cancer and Conquer Cancer FDTN

See schedule o:research: research is how we Conquer Cancer. It means everything, from understanding how Cancer impacts certain people to finding groundbreaking new ways to treat Cancer. the Conquer Cancer grants & awards program has been recognizing excellence in Clinical research, quality care, and teaching in the field of Oncology since 1984, when the program originally began under the purview of asco. Conquer Cancer funds the entire spectrum of research activities related to Cancer prevention, screening, treatment, and outcomes research in all Cancer types, and supports progress by funding Cancer researchers at all stages of their careers, enabling Oncology's best and brightest to pursue promising research. Conquer Cancer and asco have funded more than $158 million in Cancer research grants to over 2,600 recipients in 80 countries. Highlights of 2022 research activities and accomplishments include:research professorship (rp): $500,000 provided one (1) five-year award to an outstanding researcher who has made, and is continuing to make, significant contributions in breast Cancer research and will dedicate their time in training future breast Cancer researchers. This professorship is designed with the primary goal of increasing diversity in the leadership of the Oncology workforce and Cancer research. *advanced Clinical research award (acra): $900,000 provided two (2) three-year awards to support physician-scientists committed to performing original, Clinical Cancer research with a patient-oriented focus. Both awards supported diversity/inclusion, focusing on breast Cancer. *career development award (cda): $4,400,000 provided twenty-two (22) three-year awards intended to support Clinical research to Clinical investigators who have received their initial faculty appointments and are establishing independent Clinical Cancer research programs. *young investigator award (yia): $4,820,000 provided ninety-six (96) one-year awards designed to encourage and promote high-quality research in Clinical Oncology by providing funds to promising investigators during the transition from a fellowship program to a faculty appointment. *global Oncology young investigator award: $291,500 provided six (6) one-year awards to early-career investigators to encourage and promote quality research in global Oncology and to develop the next generation of researchers to address global health needs.this is a mentored award and the research project is conducted under the guidance of a scientific mentor. *international innovation grant: $94,838 provided five (5) one-year awards in support of novel and innovative projects that have the potential to reduce the Cancer burden in local communities, while also potentially discovering interventions transferable to Clinical care in other low or middle resource country settings.through its everygrant program, Conquer Cancer utilizes its expertise in grants administration and program management to collaborate with other organizations to develop and deliver programs that make a difference to Cancer care teams and patients everywhere.
See schedule o:quality & access to care: remarkable advances in Cancer medicine are occurring more and more frequently, yet the full promise of such progress cannot be realized until high quality Cancer care is available to everyone. Conquer Cancer is keenly aware of the potentially fatal divide between those with access to the fruits of research and timely care and those without. We seek to confront these disparities and improve the outlook for every person touched by Cancer by supporting programs that increase access to care in all communities, including those that are underserved.
See schedule o:professional education: Conquer Cancer supports the efforts of asco to provide education programs in the us and internationally which promote the vital exchange of ideas and latest developments that lead to world-class care, everywhere. Funds from Conquer Cancer are used to support asco's scientific and educational programs through both meetings and electronic education offerings. Highlights of the professional educational and scientific programs supported by Conquer Cancer and presented to the public in 2022 include the following: * asco annual meeting: the asco annual meeting is considered the premier educational and scientific event in the Oncology community with more than 42,000 participants worldwide in 2022. the annual meeting provides a forum to join global Cancer experts and discover the latest innovations in Cancer research and education while addressing the need for every patient to receive the highest quality Cancer care available. *gastrointestinal cancers (gi) symposium: this is the premier multidisciplinary gi Cancer scientific and educational meeting. the gi symposium gives healthcare providers across multiple disciplines and professions the opportunity to receive critical updates and recommendations to improve the care of patients with gi cancers. *genitourinary cancers (gu) symposium: this is the preeminent genitourinary Oncology event, addressing the multidisciplinary needs of physicians and other members of the Cancer care and research community who diagnose, treat, and study genitourinary malignancies. the gu symposium provides the latest strategies in screening, diagnosis, treatment, management and controversies in the field of genitourinary cancers. *quality care symposium: this is an unparalleled opportunity to leverage the most up-to-date science and discover proven strategies and tools critical to making key decisions that can reduce disparities in care for every patient, every day, everywhere. *merit awards: 240,000 provided two hundred thirty-six (236) merit awards promote Clinical research by awarding young scientists whose research is addressed in high quality abstracts submitted to asco meetings with an opportunity to present their research at asco scientific meetings and disease specific symposia. *medical student rotation for underrepresented populations (msr): $238,000 provided twenty-eight (28) medical student rotations. the msr provides a 4-week Clinical or Clinical research rotation for u.s. medical students from populations underrepresented in medicine who are interested in pursuing Oncology as a career.

Grants made by Conquer Cancer and Conquer Cancer FDTN

GranteeGrant descriptionAmount
American Society of Clinical Oncology (ASCO)Charitable Assistance$9,233,468
Memorial Sloan-Kettering Cancer CenterCda, Yia$1,250,000
Ohio State University / Erie County 4-H Horse Advisory ComiArca, Cda, Yia$800,000
...and 34 more grants made totalling $17,340,792

Who funds Conquer Cancer and Conquer Cancer FDTN

Grants from foundations and other nonprofits
GrantmakerDescriptionAmount
American Society of Clinical Oncology (ASCO)Contribution$3,514,500
THE Breast Cancer Research FoundationMedical Research$1,707,918
Mckesson FoundationCharitable$920,000
...and 57 more grants received totalling $8,967,963

Personnel at Conquer Cancer and Conquer Cancer FDTN

NameTitleCompensation
Clifford Hudis Facp FascoChief Executive Officer As of 6 and 27 and 2016$0
Nancy DalyChief Executive Officer and Executive Vice President$0
Adrien DickersonBoard Member
Linda A JensenExecutive Vice President and Chief Financial Officer$0
Eileen MelnickChief Philanthropy Officer
...and 10 more key personnel

Financials for Conquer Cancer and Conquer Cancer FDTN

RevenuesFYE 12/2022
Total grants, contributions, etc.$31,125,188
Program services$363,476
Investment income and dividends$1,978,770
Tax-exempt bond proceeds$0
Royalty revenue$0
Net rental income$0
Net gain from sale of non-inventory assets$-141,082
Net income from fundraising events$-192,660
Net income from gaming activities$0
Net income from sales of inventory$0
Miscellaneous revenues$0
Total revenues$33,133,692

Form 990s for Conquer Cancer and Conquer Cancer FDTN

Fiscal year endingDate received by IRSFormPDF link
2022-122023-09-28990View PDF
2021-122022-10-10990View PDF
2020-122021-10-19990View PDF
2019-122021-02-19990View PDF
2018-122020-01-23990View PDF
...and 9 more Form 990s
Data update history
August 10, 2024
Received grants
Identified 16 new grant, including a grant for $920,000 from Mckesson Foundation
May 18, 2024
Received grants
Identified 4 new grant, including a grant for $1,707,918 from THE Breast Cancer Research Foundation
January 29, 2024
Updated personnel
Identified 1 new personnel
January 3, 2024
Received grants
Identified 18 new grant, including a grant for $3,514,500 from American Society of Clinical Oncology (ASCO)
December 2, 2023
Posted financials
Added Form 990 for fiscal year 2022
Nonprofit Types
Grantmaking organizationsDisease research fundraisersMedical research organizationsChapter / child organizationsCharities
Issues
HealthDiseases and disordersMedical disciplinesCancer
Characteristics
Funds one specific organizationMembershipsProvides grantsConducts researchFundraising eventsOperates internationallyNational levelEndowed supportCommunity engagement / volunteeringGala fundraisersTax deductible donationsNo full-time employeesAccepts online donations
General information
Address
2318 Mill Rd Suite 800
Alexandria, VA 22314
Metro area
Washington-Arlington-Alexandria, DC-VA-MD-WV
County
Alexandria city, VA
Website URL
conquer.org/ 
Phone
(571) 483-1700
Facebook page
ConquerCancerFoundation 
Twitter profile
@iconquercancer 
IRS details
EIN
31-1667995
Fiscal year end
December
Taxreturn type
Form 990
Year formed
1999
Eligible to receive tax-deductible contributions (Pub 78)
Yes
Categorization
NTEE code, primary
H11: Medical Research Single Organization Support
NAICS code, primary
813212: Health and Disease Research Fundraising Organizations
Parent/child status
Subordinate organization
California AB-488 details
AB 488 status
May Operate or Solicit for Charitable Purposes
Charity Registration status
Current - Awaiting Reporting
FTB status revoked
Not revoked
AG Registration Number
115304
FTB Entity ID
None yet
AB 488 data last updated ("as-of") date
2024-11-20
Free account sign-up

Want updates when Conquer Cancer and Conquer Cancer FDTN has new information, or want to find more organizations like Conquer Cancer and Conquer Cancer FDTN?

Create free Cause IQ account